company background image
AGP logo

AGP KASE:AGP Stock Report

Last Price

PK₨90.27

Market Cap

PK₨25.3b

7D

-0.5%

1Y

67.2%

Updated

22 Jun, 2024

Data

Company Financials

AGP Stock Overview

Manufactures, sells, wholesales, distributes, exports, imports, markets, deals in pharmaceutical and healthcare products under licensing arrangements in Pakistan.

AGP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends1/6

AGP Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AGP
Historical stock prices
Current Share PricePK₨90.27
52 Week HighPK₨97.00
52 Week LowPK₨46.00
Beta0.72
11 Month Change-0.27%
3 Month Change28.32%
1 Year Change67.17%
33 Year Change-16.45%
5 Year Change31.72%
Change since IPO7.46%

Recent News & Updates

Recent updates

Shareholder Returns

AGPPK PharmaceuticalsPK Market
7D-0.5%-0.7%2.0%
1Y67.2%87.9%65.5%

Return vs Industry: AGP underperformed the PK Pharmaceuticals industry which returned 87.9% over the past year.

Return vs Market: AGP exceeded the PK Market which returned 65.5% over the past year.

Price Volatility

Is AGP's price volatile compared to industry and market?
AGP volatility
AGP Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement5.3%
10% most volatile stocks in PK Market8.2%
10% least volatile stocks in PK Market3.2%

Stable Share Price: AGP has not had significant price volatility in the past 3 months.

Volatility Over Time: AGP's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19891,574Muhammad Nasirwww.agp.com.pk

AGP Limited manufactures, sells, wholesales, distributes, exports, imports, markets, deals in pharmaceutical and healthcare products under licensing arrangements in Pakistan. The company offers products in the areas of aminoglycosides, angiotensin II antagonist, anti epileptics, anti-gout, anti-infective antidiarrheal, anti-inflammatory enzyme, antidiarrheal microorganisms, antifibrinolytic, antihistamines systemic, antileuk anti-ashtm sys, antineoplastic agent, anti-obesity, antirheumatic non-steroid, antispasmodic and anticholinergic plain, atypical antipsychotics, biguanide and S-urea combs, bile stone therapy, calcium, calcium channel blocker, cephalosporins oral and inject, DPP-IV Inh and biguanide comb, DPP-IV Inh A-diab plain, expectorants, eye tonics and eye vitamins, fluoroquinolones, glitazone and S-urea combs, glitazone A-diabs plain, glitazone and biguanide combinations, hepatitis C antivirals, iron combination products, iron plain, lipid modifying agents combinations, menthae piperitae aetheroleum, muscle relaxants central, narcotic analgesic, and non-narcotic analgesic. It provides narcotic analgesic, non-narcotic analgesics, nucleoside reverse transcriptase inhibitors, Oth anti-anaem folic acid, other musculoskeletal products, other stomach disorder products, proton pump inhibitor, psycholeptic antidepressant, SGLT2 inhibitors antidiabetic and biguanide, sitagliptin, SSRI antidepressants, sulphonylurea, systemic vasoprotectives, tonic, topical antihaemorrhoidal, urinary anti-infectives, urinary incontinence prd, vitamin B12, vitamin B12 plain, vitamin C combinations, vitamin D3, and xanthine-systemic products.

AGP Limited Fundamentals Summary

How do AGP's earnings and revenue compare to its market cap?
AGP fundamental statistics
Market capPK₨25.28b
Earnings (TTM)PK₨1.61b
Revenue (TTM)PK₨20.76b

15.7x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGP income statement (TTM)
RevenuePK₨20.76b
Cost of RevenuePK₨9.66b
Gross ProfitPK₨11.10b
Other ExpensesPK₨9.49b
EarningsPK₨1.61b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.75
Gross Margin53.47%
Net Profit Margin7.75%
Debt/Equity Ratio40.0%

How did AGP perform over the long term?

See historical performance and comparison

Dividends

2.8%

Current Dividend Yield

43%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.